Analysis of the efficacy and safety of direct antiviral drugs combined with ribavirin in elderly patients with compensated liver cirrhosis caused by genotype 1b chronic hepatitis C

Abstract

Abstract: Objective To evaluate the efficacy and safety of direct-acting antiviral drugs in combination with ribavirin in elderly patients with compensated liver cirrhosis caused by genotype 1b chronic hepatitis C.Methods From April 2021 to April 2022, a total of 120 elderly patients with compensated cirrhosis caused by genotype 1b chronic hepatitis C were treated with a combination of direct-acting antiviral drug and ribavirin in our hospital. We evaluated the seroconversion rate of hepatitis C virus (HCV) RNA, virology response, liver function indicators, and adverse reactions to assess the efficacy and safety of this treatment regimen.Results The seroconversion rate of HCV RNA (66.7%, 82.5%, 93.3%) showed a progressive increase with the duration of treatment time (P<0.05). As the treatment period extended, the sustained virological response rate (93.3%, 89.2%, 86.7%) gradually decreased, but the difference was not statistically significant (P>0.05). Compared to the pre-treatment levels of total bilirubin (TBil), alanine transaminase (ALT), and aspartate transaminase (AST) [(21.6 ± 3.2) μmol/L, (128.7 ± 14.6) U/L, (83.6 ± 9.3) U/L], the levels were significantly decreased after treatment [(17.1 ± 2.4) μmol/L, (34.2 ± 5.8) U/L, (26.4 ± 4.7) U/L] (P<0.05). During the course of treatment, some patients experienced adverse reactions, including 10 cases of dizziness and fatigue ,(8.3%), 5 cases of abnormal blood pressure (4.2%), 5 cases of elevated blood sugar (4.2%), and 4 cases of gastrointestinal reactions (3.3%). All of these adverse reactions resolved after symptomatic treatment, and the patients were able to tolerate them.Conclusion The use of direct antiviral drugs combined with ribavirin in the treatment of elderly patients with compensated liver cirrhosis caused by genotype 1b chronic hepatitis C has demonstrated good efficacy. It has been shown to promote the seroconversion of HCV RNA, achieve sustained virological response, and improve the level of liver function indicators. Furthermore, this treatment regimen has a high level of clinical safety.

Key words: Chronic hepatitis C, Genotype 1b, Compensatory cirrhosis, Direct antiviral drugs, Ribavirin

SU Jing-bo, CAO Guang-hua. Analysis of the efficacy and safety of direct antiviral drugs combined with ribavirin in elderly patients with compensated liver cirrhosis caused by genotype 1b chronic hepatitis C[J]. Chinese Hepatolgy, 2023, 28(12): 1459-1461.

References

[1] Lupberger J, Croonenborghs T, Suarez AAR, et al. Combined analysis of metabolomes, proteomes, and transcriptomes of hepatitis C virus-infected cells and liver to identify pathways associated with disease development[J]. Gastroenterology,2019,157(2):537-551.
[2] Borgia SM, Hedskog C, Parhy B, et al. Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes[J]. J Infect Dis,2018,218(11):1722-1729.
[3] 任姗, 金怡, 柳雅立, 等. 聚乙二醇干扰素联合利巴韦林治疗对基因1b型慢性丙型肝炎患者预存耐药相关替代的差异性分析[J]. 北京医学,2020,42(6):479-484,488.
[4] 贺秋凤, 胡蓉, 曾义岚, 等. 索磷布韦/维帕他韦联合或不联合利巴韦林治疗基因3型慢性丙型肝炎病毒感染者的疗效及安全性:一项真实世界研究[J]. 中国肝脏病杂志(电子版)2022,14(1):6-13.
[5] Enomoto M, Ikura Y, Tamori A, et al. Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C[J]. United European Gastroenterol J,2018,6(9):1391-1400.
[6] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志,2020,23(1):后插33-后插52.
[7] Wehmeyer MH, Ingiliz P, Christensen S, et al. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)[J]. J Med Virol,2018,90(2):304-312.
[8] Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review[J]. Gastroenterology,2019,156(8):2149-2157.
[9] Ogawa E, Furusyo N, Nakamuta M, et al. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: results from a multicenter, real-world cohort study[J]. Hepatol Res,2019,49(6):617-626.
[10] Mohamed AA, Omar AAA, El-Awady RR, et al. MiR-155 and MiR-665 role as potential non-invasive biomarkers for hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection[J]. J Transl Intern Med,2020,8(1):32-40.
[11] Damiani G, Franchi C, Pigatto P, et al. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents[J]. World J Hepatol,2018,10(2):329.
[12] Goñi Esarte S, Juanbeltz R, Martinez-Baz I, et al. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents[J]. Rev Esp Enferm Dig,2019,111(6):445-452.
[13] Tamori A, Abiru S, Enomoto H, et al. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy[J]. J Viral Hepatitis,2018,25(5):608-611.
[14] 揭育胜, 袁静, 张晓红, 等. 奥比帕利联合达塞布韦用于中国基因1b型丙型肝炎病毒慢性感染的真实世界研究[J]. 中华肝脏病杂志,2019,27(2):123-127.
[15] Singh S, Facciorusso A, Loomba R, et al. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis[J]. Clin Gastroenterol H,2018,16(1):27-38.
[16] 侯艺辉, 刘腾飞, 赵晓青, 等. 不同直接抗病毒药物方案对基因1b型慢性丙型肝炎及代偿期丙型肝炎肝硬化临床结局的影响[J]. 临床肝胆病杂志,2020,36(1):84-87.
[17] Ji F, Yeo YH, Wei MT, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis[J]. J Hepatol,2019,71(3):473-485.
[18] Mettke F, Schlevogt B, Deterding K, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis[J]. Aliment Pharm Ther,2018,47(4):516-525.